Molecular Therapies for Inherited Retinal Diseases—Current Standing, Opportunities and Challenges
Open accessThe DOI matches its Crossref record; 230 of the 235 references it cites were found in a registry or an index.
Abstract
Inherited retinal diseases (IRDs) are both genetically and clinically highly heterogeneous and have long been considered incurable. Following the successful development of a gene augmentation therapy for biallelic RPE65-associated IRD, this view has changed. As a result, many different therapeutic approaches are currently being developed, in particular a large variety of molecular therapies. These are depending on the severity of the retinal degeneration, knowledge of the pathophysiological mechanism underlying each subtype of IRD, and the therapeutic target molecule. DNA therapies include approaches such as gene augmentation therapy, genome editing and optogenetics. For some genetic subtypes of IRD, RNA therapies and compound therapies have also shown considerable therapeutic potential. In this review, we summarize the current state-of-the-art of various therapeutic approaches, including the pros and cons of each strategy, and outline the future challenges that lie ahead in the combat against IRDs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Moreover, another large gene, CEP290, can be rescued on the mRNA level by antisense oligonucleotides (AONs; QR-110 for Leber congenital amaurosis (LCA), with CEP290; QR-421a for LCA with USH2A) [19].”
From Recombinant Adeno-Associated Viral Vectors (rAAV)-Vector Elements in Ocular Gene Therapy Clinical Trials and Transgene Expression and Bioactivity Assays (2020) · cites this paper as [19]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Induction of Pluripotent Stem Cells from Adult Human Fibroblasts by Defined Factors
Takahashi, K., Tanabe, K., Ohnuki, M., Narita, M., Ichisaka, T., Tomoda, K., & Yamanaka, S. (2007) · Cell · doi:10.1016/j.cell.2007.11.019 · Cited by 20,221
DNA targeting specificity of RNA-guided Cas9 nucleases
Hsu, P. D., Scott, D. A., Weinstein, J. A., Ran, F. A., Konermann, S., Agarwala, V., Li, Y., Fine, E. J., Wu, X., Shalem, O., et al. (2013) · Nature Biotechnology · doi:10.1038/nbt.2647 · Cited by 4,741
ZFN, TALEN, and CRISPR/Cas-based methods for genome engineering
Gaj, T., Gersbach, C. A., & Barbas, C. F. (2013) · Trends in Biotechnology · doi:10.1016/j.tibtech.2013.04.004 · Cited by 3,820
Update on Key Emerging Challenges in Cystic Fibrosis
Jennings, M. T., Riekert, K. A., & Boyle, M. P. (2014) · Medical Principles and Practice · doi:10.1159/000357646 · Cited by 3,648
Isolation of a Common Receptor for Coxsackie B Viruses and Adenoviruses 2 and 5
Bergelson, J. M., Cunningham, J. A., Droguett, G., Kurt-Jones, E. A., Krithivas, A., Hong, J. S., Horwitz, M. S., Crowell, R. L., & Finberg, R. W. (1997) · Science · doi:10.1126/science.275.5304.1320 · Cited by 3,102
Neurodegenerative Disorders: Parkinson's Disease and Huntington's Disease
Hague, S., Klaffke, S., & Bandmann, O. (2006) · IMPERIAL COLLEGE PRESS eBooks · doi:10.1142/9781860948961_0007 · Cited by 2,767
Rationally engineered Cas9 nucleases with improved specificity
Slaymaker, I. M., Gao, L., Zetsche, B., Scott, D. A., Yan, W. X., & Zhang, F. (2016) · Science · doi:10.1126/science.aad5227 · Cited by 2,414 · cited 1×
“To overcome this aspect, researchers have developed different strategies—(i) using ribonucleoproteins (RNPs) as a form of delivery [55]; (ii) titrating the concentration of gRNA and Cas9 or using two gRNAs flanking the target region [56]; (iii) adding two additional guanine bases at the 5’ end of the gRNA sequence for…”
BackgroundRNA targeting with CRISPR–Cas13
Abudayyeh, O. O., Gootenberg, J. S., Essletzbichler, P., Han, S., Joung, J., Belanto, J. J., Verdine, V., Cox, D. B. T., Kellner, M. J., Regev, A., et al. (2017) · Nature · doi:10.1038/nature24049 · Cited by 2,093
Kim, S., Kim, D., Cho, S. W., Kim, J., & Kim, J.-S. (2014) · Genome Research · doi:10.1101/gr.171322.113 · Cited by 1,856
Cox, D. B. T., Gootenberg, J. S., Abudayyeh, O. O., Franklin, B., Kellner, M. J., Joung, J., & Zhang, F. (2017) · Science · doi:10.1126/science.aaq0180 · Cited by 1,834
Cited by
Cremers, F. P. M., Lee, W., Collin, R. W. J., & Allikmets, R. (2020) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2020.100861 · Cited by 315
“…another subtype of inherited retinal disease that is caused by bi-allelic mutations in RPE65, has provided hope for many visually impaired individuals, and is paralleled by the development of similar therapeutic strategies for other genes underlying these disorders (Vazquez-Dominguez et al., 2019).”
BackgroundSelf-citationPontikos, N., Arno, G., Jurkute, N., Schiff, E., Ba-Abbad, R., Malka, S., Gimenez, A., Georgiou, M., Wright, G., Armengol, M., et al. (2020) · Ophthalmology · doi:10.1016/j.ophtha.2020.04.008 · Cited by 254
“Adenoassociated viruses have been a vector of choice for ocular gene therapy trials, targeting retinal cells with relatively low immunogenicity, but their capacity is limited.(5) We explored transcript lengths and relationships with numbers of families affected.”
BackgroundInfluentialHerrera-Barrera, M., Ryals, R. C., Gautam, M., Jozic, A., Landry, M., Korzun, T., Gupta, M., Acosta, C., Stoddard, J., Reynaga, R., et al. (2023) · Science Advances · doi:10.1126/sciadv.add4623 · Cited by 239
“Luxturna has established the safety and efficacy of gene augmentation via subretinal delivery, and, now, many different AAV gene therapies are under preclinical and/or clinical development (7, 8).”
BackgroundSchneider, N., Sundaresan, Y., Gopalakrishnan, P., Beryozkin, A., Hanany, M., Levanon, E. Y., Banin, E., Ben-Aroya, S., & Sharon, D. (2022) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2021.101029 · Cited by 224
A look into retinal organoids: methods, analytical techniques, and applications
Afanasyeva, T. A. V., Corral-Serrano, J. C., Garanto, A., Roepman, R., Cheetham, M. E., & Collin, R. W. J. (2021) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-021-03917-4 · Cited by 117
Self-citation
Metadata
- Authors
- Vázquez-Domínguez, I., Garanto, A., & Collin, R. W. J.
- Affiliations
- Radboud University Nijmegen (NL)
- Corresponding author
- Garanto, Alejandro
- Collin, Rob W. J.
- Venue
- Genes
- Publisher
- MDPI AG
- Published
- 2019-08-28
- Volume
- 10
- Issue
- 9
- Pages
- 654
- ISSN
- 2073-4425 (ISSN-L)
- PMC
- PMC6770110
- OpenAlex
- W2971284229
- Cited by
- 80
- References
- 235
- Citations by year
- 2026: 2 · 2025: 3 · 2024: 7 · 2023: 12 · 2022: 19 · 2021: 24 · 2020: 11 · 2019: 2
- FWCI
- 1.24
- Type
- journal article
- Language
- en
- Open access
- gold
- dx.doi.org
- Licence
- Locations
- Genes (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- Radboud Repository (Radboud University) (submittedVersion)
- Radboud Repository (Radboud University) (submittedVersion, other-oa)
- Funders
- Foundation Fighting Blindness (PPA-0517-0717-RAD)
- UitZicht (2015-31, 2018-21)
- ZonMw (Off Road 91215203)
- Topics
- Health Sciences › Medicine › Ophthalmology › Retinal Development and Disorders
- Health Sciences › Medicine › Ophthalmology › Retinal Diseases and Treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Keywords
- inherited retinal disease, gene therapy, gene augmentation therapy, RPE65, genome editing, optogenetics, RNA therapeutics, retinal degeneration, molecular therapy
- MeSH terms
- Clinical Trials as Topic, Humans, Retinal Degeneration, Genetic Therapy, Gene Transfer Techniques, Neuroprotective Agents
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Molecular Therapies for Inherited Retinal Diseases—Current Standing, Opportunities and Challenges. https://app.cochat.ai/papers/10.3390/genes10090654
- The paper
- Vázquez-Domínguez, I., Garanto, A., & Collin, R. W. J. (2019). Molecular Therapies for Inherited Retinal Diseases—Current Standing, Opportunities and Challenges. Genes. https://doi.org/10.3390/genes10090654
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.